Pulmonary pharmacology and therapeutics

Pulmonary pharmacology and therapeutics

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton

ERJ Open Research Oct 2019, 5 (4) 00061-2019; DOI: 10.1183/23120541.00061-2019
A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation
Aldo Iacono, Marniker Wijesinha, Keshava Rajagopal, Natalia Murdock, Irina Timofte, Bartley Griffith, Michael Terrin

ERJ Open Research Oct 2019, 5 (4) 00167-2019; DOI: 10.1183/23120541.00167-2019
Prevalence of oral corticosteroid use in the German severe asthma population
Christian Taube, Peter Bramlage, Annette Hofer, Dörte Anderson

ERJ Open Research Oct 2019, 5 (4) 00092-2019; DOI: 10.1183/23120541.00092-2019
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
Andrew Menzies-Gow, Jonathan Corren, Elisabeth H. Bel, Jorge Maspero, Liam G. Heaney, Mark Gurnell, Peter Wessman, Ubaldo J. Martin, Shahid Siddiqui, Esther Garcia Gil

ERJ Open Research Jul 2019, 5 (3) 00009-2019; DOI: 10.1183/23120541.00009-2019
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
Benoît Bédat, Jérôme Plojoux, Jade Noel, Anna Morel, Jonathan Worley, Frédéric Triponez, Wolfram Karenovics

ERJ Open Research Jul 2019, 5 (3) 00084-2019; DOI: 10.1183/23120541.00084-2019
Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
Jaco Voorham, Massimo Corradi, Alberto Papi, Claus F. Vogelmeier, Dave Singh, Leonardo M. Fabbri, Marjan Kerkhof, Janwillem H. Kocks, Victoria Carter, David Price

ERJ Open Research Jul 2019, 5 (3) 00106-2019; DOI: 10.1183/23120541.00106-2019
Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial
Vijay Kunadian, Nina Wilson, Deborah D. Stocken, Hani Ali, Elaine McColl, Graham Burns, Nicola Howe, Andrew Fisher, Anthony De Soyza

ERJ Open Research Jul 2019, 5 (3) 00110-2019; DOI: 10.1183/23120541.00110-2019
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
Jennifer L. Taylor-Cousar, Marcus A. Mall, Bonnie W. Ramsey, Edward F. McKone, Elizabeth Tullis, Gautham Marigowda, Charlotte M. McKee, David Waltz, Samuel M. Moskowitz, Jessica Savage, Fengjuan Xuan, Steven M. Rowe

ERJ Open Research Apr 2019, 5 (2) 00082-2019; DOI: 10.1183/23120541.00082-2019
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus
Shelby Daniel-Wayman, Shamira Shallom, Nabila Azeem, Kenneth N. Olivier, Adrian M. Zelazny, D. Rebecca Prevots

ERJ Open Research Apr 2019, 5 (2) 00154-2018; DOI: 10.1183/23120541.00154-2018
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Christopher J. Ryerson, Martin Kolb, Luca Richeldi, Joyce Lee, Daniel Wachtlin, Susanne Stowasser, Venerino Poletti

ERJ Open Research Apr 2019, 5 (2) 00127-2018; DOI: 10.1183/23120541.00127-2018

Main menu

User menu

Search

Pulmonary pharmacology and therapeutics

Pages

Contact us